Prana Therapies is a clinical-stage biotechnology company pioneering a new generation of multispecific antibodies designed to deliver best-in-disease therapies across a broad range of diseases.
Our proprietary INSPIRE platform combines complementary therapeutic mechanisms into a single drug, to create differentiated medicines with the potential for enhanced efficacy and infrequent dosing.
Prana is advancing a wholly owned pipeline of multispecific therapeutics, initially focused on respiratory and dermatologic diseases, with discovery-stage programs expanding across therapeutic areas.
INSPIRE is Prana's proprietary multispecific antibody platform, designed to overcome key limitations of conventional multispecific formats and create medicines with the efficacy, pharmacokinetics, and drug-like properties needed to deliver a differentiated product profile.
INSPIRE combines complementary therapeutic mechanisms within a single, fully IgG-based molecule. Our candidates are designed for enhanced efficacy, extended half-life, low immunogenicity, high-concentration subcutaneous delivery, and infrequent, at-home dosing, while maintaining favorable stability and manufacturability.
The platform is modular and scalable, enabling Prana to generate differentiated candidates across targets and therapeutic areas. PRA-216, our lead clinical program, provides the first clinical validation of INSPIRE.
Explore the latest company news, scientific presentations, and publications from Prana Therapies.
Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced positive Phase 1 results for PRA-216, its lead clinical program and a fully human, half-life-extended bispecific antibody developed on Prana’s proprietary INSPIRE platform.
Prana Therapies presents late-breaker poster at The ERS Congress 2026 in Barcelona, Spain.
Prana brings together an experienced team of scientists, drug developers, and industry leaders with a track record of discovering and advancing innovative therapeutics from concept through clinical development.
For partnering, media, and other inquiries, please contact us at info@pranatherapies.com